Literature DB >> 22231233

SLE in 2011: Deciphering the role of NETs and networks in SLE.

Thomas Dörner1.   

Abstract

From neutrophil extracellular traps to genetic networks that underlie the disease and new targeted therapies, important advances in 2011 improve our understanding of the pathogenesis of systemic lupus erythematosus and mark the beginning of our ability to treat it effectively.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22231233     DOI： 10.1038/nrrheum.2011.200

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

1.  Neutrophil extracellular traps kill bacteria.

Authors:  Volker Brinkmann; Ulrike Reichard; Christian Goosmann; Beatrix Fauler; Yvonne Uhlemann; David S Weiss; Yvette Weinrauch; Arturo Zychlinsky
Journal:  Science       Date:  2004-03-05       Impact factor: 47.728

2.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

3.  Dissecting the immune cell mayhem that drives lupus pathogenesis.

Authors:  Joseph E Craft
Journal:  Sci Transl Med       Date:  2011-03-09       Impact factor: 17.956

4.  Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus.

Authors:  Roberto Lande; Dipyaman Ganguly; Valeria Facchinetti; Loredana Frasca; Curdin Conrad; Josh Gregorio; Stephan Meller; Georgios Chamilos; Rosalie Sebasigari; Valeria Riccieri; Roland Bassett; Hideki Amuro; Shirou Fukuhara; Tomoki Ito; Yong-Jun Liu; Michel Gilliet
Journal:  Sci Transl Med       Date:  2011-03-09       Impact factor: 17.956

5.  Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c⁺ B-cell population is important for the development of autoimmunity.

Authors:  Anatoly V Rubtsov; Kira Rubtsova; Aryeh Fischer; Richard T Meehan; Joann Z Gillis; John W Kappler; Philippa Marrack
Journal:  Blood       Date:  2011-05-04       Impact factor: 22.113

6.  Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.

Authors:  Elizabeth A Leadbetter; Ian R Rifkin; Andreas M Hohlbaum; Britte C Beaudette; Mark J Shlomchik; Ann Marshak-Rothstein
Journal:  Nature       Date:  2002-04-11       Impact factor: 49.962

7.  A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Authors:  Daniel J Wallace; William Stohl; Richard A Furie; Jeffrey R Lisse; James D McKay; Joan T Merrill; Michelle A Petri; Ellen M Ginzler; W Winn Chatham; W Joseph McCune; Vivian Fernandez; Marc R Chevrier; Z John Zhong; William W Freimuth
Journal:  Arthritis Rheum       Date:  2009-09-15

8.  AIRE regulates T-cell-independent B-cell responses through BAFF.

Authors:  Emma Lindh; Sara M Lind; Evelina Lindmark; Signe Hässler; Jaakko Perheentupa; Leena Peltonen; Ola Winqvist; Mikael C I Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-14       Impact factor: 11.205

9.  Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes.

Authors:  Kimberly E Taylor; Sharon A Chung; Robert R Graham; Ward A Ortmann; Annette T Lee; Carl D Langefeld; Chaim O Jacob; M Ilyas Kamboh; Marta E Alarcón-Riquelme; Betty P Tsao; Kathy L Moser; Patrick M Gaffney; John B Harley; Michelle Petri; Susan Manzi; Peter K Gregersen; Timothy W Behrens; Lindsey A Criswell
Journal:  PLoS Genet       Date:  2011-02-17       Impact factor: 5.917

Review 10.  Mechanisms of B cell autoimmunity in SLE.

Authors:  Thomas Dörner; Claudia Giesecke; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2011-10-27       Impact factor: 5.156
  10 in total
  9 in total

1.  C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?

Authors:  Mariam P Alexander; Fernando C Fervenza; An S De Vriese; Richard J H Smith; Samih H Nasr; Lynn D Cornell; Loren P Herrera Hernandez; Yuzhou Zhang; Sanjeev Sethi
Journal:  J Nephrol       Date:  2015-07-18       Impact factor: 3.902

2.  Dying cells and extracellular histones in AKI: beyond a NET effect?

Authors:  Diane L Rosin; Mark D Okusa
Journal:  J Am Soc Nephrol       Date:  2012-07-12       Impact factor: 10.121

Review 3.  Thrombosis as an intravascular effector of innate immunity.

Authors:  Bernd Engelmann; Steffen Massberg
Journal:  Nat Rev Immunol       Date:  2012-12-07       Impact factor: 53.106

4.  Role of nucleic acid-sensing TLRs in diverse autoantibody specificities and anti-nuclear antibody-producing B cells.

Authors:  Yi Ting Koh; John C Scatizzi; Jennifer D Gahan; Brian R Lawson; Roberto Baccala; K Michael Pollard; Bruce A Beutler; Argyrios N Theofilopoulos; Dwight H Kono
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

5.  HMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor 4.

Authors:  Jean-Marc Tadie; Hong-Beom Bae; Shaoning Jiang; Dae Won Park; Celeste P Bell; Huan Yang; Jean-Francois Pittet; Kevin Tracey; Victor J Thannickal; Edward Abraham; Jaroslaw W Zmijewski
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-01-11       Impact factor: 5.464

6.  Celastrol inhibits inflammatory stimuli-induced neutrophil extracellular trap formation.

Authors:  Y Yu; C D Koehn; Y Yue; S Li; G M Thiele; M P Hearth-Holmes; T R Mikuls; J R O'Dell; L W Klassen; Z Zhang; K Su
Journal:  Curr Mol Med       Date:  2015       Impact factor: 2.222

Review 7.  Treatment targets in systemic lupus erythematosus: biology and clinical perspective.

Authors:  Valentin Marian; Jennifer H Anolik
Journal:  Arthritis Res Ther       Date:  2012-11-30       Impact factor: 5.156

Review 8.  Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.

Authors:  Henrik E Mei; Stefanie Schmidt; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2012-11-08       Impact factor: 5.156

Review 9.  The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease.

Authors:  Sonal Mehra; Marvin J Fritzler
Journal:  J Immunol Res       Date:  2014-04-03       Impact factor: 4.818
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.